Changelog — 2026-02-17
2026-02-17
BIIB
BIOGEN INC.
Status: ACTIVE_NOT_RECRUITING → TERMINATED (Sponsor Decision) — PHASE2
NCT05798520
• Phase 2 • Status: Active, not recruiting → Terminated • Why stopped: Sponsor Decision
🚩 MAJOR
2026-02-17
GILD
GILEAD SCIENCES, INC.
Status: ACTIVE_NOT_RECRUITING → TERMINATED (Sponsor Decision) — PHASE2
NCT05629208
• Phase 2 • Status: Active, not recruiting → Terminated • Why stopped: Sponsor Decision
🚩 MAJOR
2026-02-17
M
MGNX
MACROGENICS INC
CT.gov status: NOT_YET_RECRUITING → SUSPENDED (PI requested) — PHASE2 — investigator-sponsored (collaborator: MGNX)
NCT07071961
• Phase 2 • Status: Not yet recruiting → Suspended • Why stopped: PI requested
HIGH
2026-02-17
C
CORT
CORCEPT THERAPEUTICS INC
Enrollment 1000→1143 (14%)
NCT06829537
• Enrollment 1000→1143 (+14%)
MEDIUM
2026-02-17
I
IDYA
IDEAYA Biosciences, Inc.
Primary endpoint added: Phase 2a: To determine the optimal dose of IDE196 + Crizotinib combination for Phase 2B and Phase 3 by evaluating the following: — PHASE2
NCT05987332
• Phase 2
MEDIUM
2026-02-17
N
NVMI
NOVA LTD.
Enrollment 670→509 (-24%) — NA
NCT03682991
• Na • Enrollment 670→509 (-24%)
MEDIUM
2026-02-17
B
BHVN
Biohaven Ltd.
Enrollment 10→20 (100%) — PHASE1
NCT07054684
• Phase 1 • Enrollment 10→20 (+100%)
MEDIUM
2026-02-17
I
IDYA
IDEAYA Biosciences, Inc.
Status: RECRUITING → ACTIVE_NOT_RECRUITING — PHASE2
NCT05987332
• Phase 2 • Status: Recruiting → Active, not recruiting
MEDIUM
2026-02-17
O
ONON
On Holding AG
Enrollment 100→101 (1%) — NA
NCT06595030
• Na • Enrollment 100→101 (+1%)
MEDIUM
2026-02-17
A
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Locations updated — PHASE3
NCT07037771
• Phase 3
MEDIUM
2026-02-17
C
CNTB
Connect Biopharma Holdings Ltd
Locations updated — PHASE2
NCT06940154
• Phase 2
MEDIUM
2026-02-17
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Locations updated — PHASE3
NCT07052903
• Phase 3
MEDIUM
2026-02-17
L
LXRX
LEXICON PHARMACEUTICALS, INC.
Locations updated — PHASE4
NCT07221838
• Phase 4
MEDIUM
2026-02-17
C
CNTB
Connect Biopharma Holdings Ltd
Locations updated — PHASE2
NCT06940141
• Phase 2
MEDIUM
2026-02-17
O
ONON
On Holding AG
Study arms updated — NA — investigator-sponsored (collaborator: ONON)
NCT05530460
• Na
MEDIUM
2026-02-17
O
ONON
On Holding AG
Enrollment 124→135 (9%) — NA
NCT05747703
• Na • Enrollment 124→135 (+9%)
MEDIUM
2026-02-17
O
ONON
On Holding AG
Enrollment 130→15 (-88%) — NA
NCT07271290
• Na • Enrollment 130→15 (-88%)
MEDIUM
2026-02-17
NVS
NOVARTIS AG
Enrollment 108→109 (1%) — PHASE3
NCT05888493
• Phase 3 • Enrollment 108→109 (+1%)
MEDIUM
2026-02-17
Z
ZLDPF
Zealand Pharma A/S/ADR
Enrollment 92→124 (35%) — PHASE1
NCT06682975
• Phase 1 • Enrollment 92→124 (+35%)
MEDIUM
2026-02-17
S
SNDX
Syndax Pharmaceuticals Inc
Primary endpoint added: Number of participants with dose-limiting toxicities (DLTs) (Phase 1) — PHASE1
NCT04065399
• Phase 1
MEDIUM
2026-02-17
S
SNDX
Syndax Pharmaceuticals Inc
Enrollment 413→447 (8%) — PHASE1
NCT04065399
• Phase 1 • Enrollment 413→447 (+8%)
MEDIUM
2026-02-17
BMY
BRISTOL MYERS SQUIBB CO
Enrollment 400→418 (4%)
NCT06851065
• Enrollment 400→418 (+4%)
MEDIUM
2026-02-17
ABBV
AbbVie Inc.
Enrollment 74→73 (-1%) — PHASE1
NCT06774313
• Phase 1 • Enrollment 74→73 (-1%)
MEDIUM
2026-02-17
NVS
NOVARTIS AG
Enrollment 564→1214 (115%)
NCT05344469
• Enrollment 564→1214 (+115%)
MEDIUM